The Profusa, Inc. (Nasdaq: PFSA) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. Profusa is a commercial stage digital health and medical technology company focused on tissue-integrated biosensors and its Lumee Oxygen tissue monitoring platform, and its filings offer detailed insight into its capital structure, governance, financing arrangements and listing status.
Through this page, users can review current reports on Form 8-K where Profusa discloses material events such as securities purchase agreement amendments, senior secured convertible promissory note modifications, equity line of credit approvals, Nasdaq listing notifications, and manufacturing or commercial milestones referenced in Regulation FD disclosures. These 8-K filings explain key terms of convertible notes, floor price adjustments, tranche structures and mandatory prepayment provisions tied to equity line proceeds.
Investors can also access proxy statements on Schedule 14A, which describe special meetings of stockholders convened to approve items such as potential issuance of more than 19.99% of outstanding shares upon conversion of senior secured convertible notes, increases in authorized common shares, and proposals authorizing the board to implement one or more reverse stock splits within a specified ratio range. These documents outline the board’s recommendations, voting requirements and the rationale behind each corporate action.
Additional filings include registration statements on Form S-1 and related amendments, which detail resale registrations for shares issuable upon conversion of Profusa’s notes, as well as the company’s status as an emerging growth company and smaller reporting company. Notifications of late filing on Form 12b-25 explain timing for quarterly reports when additional time is needed to finalize disclosures.
On Stock Titan, each Profusa filing is accompanied by AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand complex financing terms, proposed charter amendments, or Nasdaq compliance updates. Real-time integration with EDGAR ensures that new 8-Ks, S-1 amendments, proxy statements and other PFSA filings appear promptly, while insider transaction reports on Form 4 and periodic reports such as 10-K and 10-Q (when filed) can be browsed and compared over time.
This page is designed to help investors, analysts and other interested readers interpret Profusa’s regulatory disclosures around its Lumee biosensor platform, capital-raising activities, authorized share changes and potential reverse stock splits using concise AI explanations alongside the full official documents.
Profusa, Inc. (PFSA) is calling a virtual special stockholders’ meeting on September 18, 2026 to vote on authorizing its board to implement one or more reverse stock splits of the common stock, at ratios within a 1‑for‑2 to 1‑for‑12 range, any time up to September 18, 2028. The action would not change the 600,000,000 authorized common shares or $0.0001 par value; fractional post‑split shares would be paid out in cash. The stated goals are to regain and maintain compliance with Nasdaq Capital Market’s $1.00 minimum bid price requirement, preserve the Nasdaq listing, support access to capital (including shelf registration and an equity line of credit), and broaden potential institutional investor interest. The proxy notes PFSA has already executed reverse splits of 1‑for‑75 (February 9, 2026), 1‑for‑25 (July 7, 2026), and 1‑for‑4 (August 17, 2026) and warns that failure to approve or ineffectiveness of the new split authority could lead to Nasdaq delisting, reduced liquidity, and more constrained financing options. Because authorized shares stay the same while outstanding shares would shrink, future equity issuances could be larger relative to the reduced share count, increasing potential dilution.
Profusa, Inc. (PFSA) had a Form 4 filed by major shareholder HRT Financial LP, a ten percent owner. On August 14, 2026, HRT Financial LP reported selling 3,163 shares of Profusa common stock at $0.902 per share, leaving it with 71,035 shares held directly.
HRT FINANCIAL LP, a more than ten percent owner of Profusa, Inc., reported mixed trading in Profusa common stock. On August 13, 2026, it sold 42,411 shares at $0.888 per share. On August 12, 2026, it purchased 5,585 shares at $0.964 per share. Overall, these transactions represent a net sale of 36,826 shares.
Profusa, Inc. approved and implemented a one-for-four (1:4) reverse stock split of its common stock. The reverse split becomes effective at 12:01 a.m. Eastern Time on August 17, 2026, after which the common stock will trade on The Nasdaq Capital Market on a post-split basis under ticker PFSA with a new CUSIP 74319X405.
At the effective time, every four issued and outstanding shares of common stock will be combined into one share, with the par value remaining $0.0001 per share. The number of shares outstanding will be reduced from 2,422,906 to approximately 605,726, while authorized common shares remain at 601 million. Proportionate adjustments will be made to outstanding equity awards and warrants, including exercise prices and shares reserved under the equity incentive plan.
No fractional shares will be issued; instead, each holder entitled to a fraction will receive cash based on the closing price on the effectiveness date. Profusa also provided illustrative pre- and post-split net loss per share and weighted average shares data for 2024–2026 reporting periods.
HRT FINANCIAL LP, a ten percent owner of Profusa, Inc., reported mixed trading in the company’s common stock. On 10 August 2026 it purchased 4,016 shares at $0.944 per share, and on 11 August 2026 it sold 2,280 shares at $0.97 per share.
Profusa, Inc. reported insider trading activity by HRT FINANCIAL LP, a ten percent owner of PFSA. Over August 5–7, 2026, the holder executed a mix of open-market trades in common stock, including 926 shares purchased at $0.943 and sales totaling 1,307 shares at prices around $0.94–0.95, resulting in a net reduction of 381 shares. The Rule 10b5-1 plan checkbox was not marked for these transactions.
HRT Financial LP, listed as a ten percent owner of Profusa, Inc., reported open-market purchases of a total of 15,924 shares of common stock on August 3 and 4, 2026, at per-share prices of $0.958 and $0.954. The filing does not mark the Rule 10b5-1 trading plan checkbox.
A group of investment entities and individuals led by Ascent Partners Fund LLC reports beneficial ownership of Profusa, Inc. common stock. The group has shared voting and dispositive power over 58,749 shares of common stock, representing 9.99% of the class as of June 30, 2026, subject to a contractual ownership cap.
The stake arises from convertible promissory notes effective on several dates and a Securities Purchase Agreement (the ELOC Agreement) that allows Profusa, at its option and subject to a 9.99% beneficial ownership limitation (the Blocker), to require purchases of common stock. Ownership percentages are calculated using 186,411 shares outstanding as of May 12, 2026, adjusted for a 1-for-25 reverse stock split effective July 7, 2026, plus shares issuable upon partial note conversions and ELOC purchases, all constrained by the Blocker.
Profusa, Inc. large shareholder HRT Financial LP, identified as a ten percent owner, reported two non-derivative purchases of Profusa common stock. It bought 8,811 shares at $1.05 per share on July 31, 2026 and 1,063 shares at $1.01 on July 30, 2026, for total reported purchases of 9,874 shares.